BACKGROUND: Standard anti-Helicobacter pylori therapy may not achieve a satisfactory eradication rate. Fluoroquinolones, such as moxifloxacin, are safe and promising agents for H. pylori eradication. AIM: To compare the efficacy of two 1-week moxifloxacin-based H. pylori eradication regimens with two standard treatments. METHODS: Three hundred and twenty H. pylori-positive subjects were randomized into four groups to receive: moxifloxacin, amoxicillin, esomeprazole (Group MAE); moxifloxacin, tinidazole and esomeprazole (Group MTE); standard triple therapies with clarithromycin, amoxicillin and esomeprazole (Group CAE) or tinidazole (Group CTE) for 7 days. H. pylori status was re-assessed 6 weeks after the end of therapy by 13C urea breath test. RESULTS: Three hundred and twenty patients completed the efficacy analysis per protocol; H. pylori eradication rate in group MTE was 90% (72 of 80) and 92% (72 of 78), in group MAE was 88% (70 of 80) and 89%, (70 of 79) in Group CAE was 73% (58 of 80) and 78% (58 of 74), and in Group CTE was 75% (60 of 80) and 79% (60 of 76), respectively, in intention-to-treat and in per protocol analyses. Eradication rates of moxifloxacin-based triple therapies were significantly higher than that observed using standard triple schemes. The incidence of side effects was significantly lower in moxifloxacin groups than in control groups. CONCLUSIONS: Seven-day moxifloxacin-based triple therapies provide optimal eradication rates with a good compliance when compared with the standard triple therapy schemes.

Nista, E. C., Candelli, M., Zocco, M. A., Cazzato, I. A., Cremonini, F., Ojetti, V., Santoro, M., Finizio, R., Pignataro, G., Cammarota, G., Gasbarrini, A., -Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection., <<ALIMENTARY PHARMACOLOGY & THERAPEUTICS>>, 2005; (Maggio): 1241-1247 [http://hdl.handle.net/10807/21067]

-Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.

Nista;Enrico Celestino; Candelli;Marcello; Zocco;Maria Assunta; Cazzato;Immacolata Alessia; Cremonini;Filippo; Ojetti;Veronica; Santoro;R; Pignataro;Giulia; Cammarota;Giovanni; Gasbarrini
2005

Abstract

BACKGROUND: Standard anti-Helicobacter pylori therapy may not achieve a satisfactory eradication rate. Fluoroquinolones, such as moxifloxacin, are safe and promising agents for H. pylori eradication. AIM: To compare the efficacy of two 1-week moxifloxacin-based H. pylori eradication regimens with two standard treatments. METHODS: Three hundred and twenty H. pylori-positive subjects were randomized into four groups to receive: moxifloxacin, amoxicillin, esomeprazole (Group MAE); moxifloxacin, tinidazole and esomeprazole (Group MTE); standard triple therapies with clarithromycin, amoxicillin and esomeprazole (Group CAE) or tinidazole (Group CTE) for 7 days. H. pylori status was re-assessed 6 weeks after the end of therapy by 13C urea breath test. RESULTS: Three hundred and twenty patients completed the efficacy analysis per protocol; H. pylori eradication rate in group MTE was 90% (72 of 80) and 92% (72 of 78), in group MAE was 88% (70 of 80) and 89%, (70 of 79) in Group CAE was 73% (58 of 80) and 78% (58 of 74), and in Group CTE was 75% (60 of 80) and 79% (60 of 76), respectively, in intention-to-treat and in per protocol analyses. Eradication rates of moxifloxacin-based triple therapies were significantly higher than that observed using standard triple schemes. The incidence of side effects was significantly lower in moxifloxacin groups than in control groups. CONCLUSIONS: Seven-day moxifloxacin-based triple therapies provide optimal eradication rates with a good compliance when compared with the standard triple therapy schemes.
Inglese
Nista, E. C., Candelli, M., Zocco, M. A., Cazzato, I. A., Cremonini, F., Ojetti, V., Santoro, M., Finizio, R., Pignataro, G., Cammarota, G., Gasbarrini, A., -Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection., <<ALIMENTARY PHARMACOLOGY & THERAPEUTICS>>, 2005; (Maggio): 1241-1247 [http://hdl.handle.net/10807/21067]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/21067
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact